Halozyme Therapeutics has agreed to acquire US-based Elektrofi in a deal worth up to $900m, which will see it add microparticle capabilities to its portfolio of drug delivery technologies. Halozyme will purchase fellow subcutaneous drug delivery specialist Elektrofi for $750m upfront, along with with three separate $50m milestone payments. Elektrofi will receive these payments if three products, which are currently undisclosed, are approved following the takeover. Elektrofi’s platform, called Hyercon, cr ...